While the combination is effective in enhancing cancer cell inhibition in MCF-7/FGFR1 cells, the synergistic effect observed in MCF-7/C cells suggests that the combination of alpelisib with FGFR1-targeting agents is also a meaningful approach for treating breast cancer with background levels of FGFR1. Here, FGFR1 is linked to cancer.